Latest Conference Content

At an education session at the American Society of Hematology Annual Meeting, Christopher R. Flowers, MD, MS, discussed current thinking in the use of routine imaging for patients who have achieved a long-term complete response in non-Hodgkin lymphoma.

The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.

A novel treatment method unveiled at the 56th Annual Meeting of the American Society of Hematology was among 4 important studies about reducing blood clots presented Sunday at the gathering in San Francisco.

Saturday's poster session on Health Services and Outcomes research featured results projecting an overall reduction in medical costs from the use of new oral anticoagulants, and new studies about the treatment of children with sickle cell disease.

Jesus F. San Miguel, MD, PhD, of the Spanish Myeloma Group, delivered the Han-Wasserman Lecture and discussed prognostic factors that allowed his research team to give early treatment to high-risk patients, improving their survival.

While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.

Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.

Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.

Patients with metastatic melanoma receiving vemurafenib following disease progression showed similar or better overall response to patients without progressive disease, according to findings from an analysis reported at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.

Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.

Nivolumab continues to show an impressive response that is both prompt and durable in patients with advanced melanoma, according to updated results from a long-term follow-up presented at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.

During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.

As the immuno-oncology landscape intensifies, a second player in the game, Merck's PD-1 inhibitor pembrolizumab (Keytruda), was recently approved for the treatment of advanced, unresectable melanoma.

A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C virus-infected patients, especially among those with mild disease.

The efficacy of oral antivirals for hepatitis C infection is a moot point. The prevailing discussion now delves into the best combinations that can target different viral genotypes, access to these combination regimens, and the subsequent dent in the budget of the patient, the health plan, or the care provider-as the case may be.

Medicare costs, Department of Veterans Affairs budgetary costs, and the economic impact on the developing world-these were some of the topics discussed at the evening session, Health Economics and Cost-Effectiveness, on the third day at The Liver Meeting 2014, held in Boston, Massachusetts, November 7 to 11, 2014.

Amidst discussions on liver care, transplants, and infections was a session on Value-Based Medicine in Hepatology, on the third day at The Liver Meeting 2014, an annual event by the American Association for the Study of Liver Disease, held in Boston, Massachusetts, from November 7 to 11, 2014. Presenters saw a huge turnout for the session, a sign of increased interest in value-based care.

A pattern is emerging in the hepatitis C virus treatment realm-of the newly approved agents, the sofosbuvir- and simeprevir-based regimens are gaining traction. A poster session on approved therapeutic agents on November 9, 2014, at the annual meeting of the American Association for the Study of Liver Disease, proved this again.

Bashar A. Aqel, MD, Mayo Clinic, Phoenix, Arizona, presented results from phase 2 of the COSMOS (Combination Of SiMeprevir and sOfosbuvir in hepatitis C virus genotype 1 infected patients) trial.

While the cost of hepatitis C treatment continues to be a major topic of debate-with the approval of simeprevir (Olysio), sofosbuvir (Sovaldi), and now the combination, sofosbuvir and ledipasvir (Harvoni)-those in favor of the treatment provide a strong research-based argument. The cost-debate is global, as shown by this cost-effectiveness study conducted in Italy.

While the cost of novel hepatitis C drugs has been rigorously debated, real-world data on the safety and efficacy of these drugs has now started showing up. A white paper released by CVS Health Research Institute in September of this year reported that in addition to the downward trend in utilization of sofosbuvir, which has cure rates of more than 95%, high discontinuation rates are being observed.

According to the CDC, hepatitis C virus infection is a common chronic disease that currently affects about 3.2 million people in the United States, and although less common it remains a significant health problem in children, according to the American Liver Foundation.

The era of accountable care and pay for performance is here, and physicians will have to embrace these novel reimbursement models. In a plenary session, Rubin Cohen, MD, FCCP, a member of the American College of Chest Physician's quality improvement committee, discussed the relationship between quality improvement and outcomes.

During a plenary session at the American College of Chest Physicians' CHEST meeting in Austin, Texas, Edgar Jimenez, MD, FCCM, vice president of critical care integration at Baylor Scott and White Health in Central Texas, discussed how to prepare for Ebola in the Intensive Care Unit (ICU) setting. Dr Jimenez began by introducing the session as a way to answer questions and to provide hospital ICU staff with key considerations for Ebola preparation in the United States.

A symposium on idiopathic pulmonary fibrosis (IPF), which was presented on behalf of InterMune, Inc, highlighted clinical data supporting the use of pirfenidone in patients with IPF. Leading the panel discussion was Steven Nathan, MD, FCCP, a principal investigator involved in studies of pirfenidone. Dr Nathan was joined by IPF experts Lisa Lancaster, MD, of Vanderbilt University Medical Center and Marilyn Glassberg, MD, of the University of Miami Health System.

The categorization of lung allograft dysfunction is changing, David Nunley, MD, clinical director of lung transplant at the University of Louisville Health Care Outpatient Center, said at the 2014 CHEST meeting in Austin, Texas.

Fear is the biggest barrier preventing providers from using social media to its fullest potential, according to Christopher Carroll, MD, social media editor at CHEST and research director for the Division of Critical Care at the Connecticut Children's Medical Center.

Dan Heath, a senior fellow at the Center for Advancement of Social Entrepreneurship at Duke University, outlined strategies for implementing change within an organization, including looking for solutions that are already present within an organization, as a solution to a large problem may already have been implemented on a small scale.